To our knowledge, therapeutic administration of albumin for MASLD has not been investigated, despite its inverse association with disease severity, and its well-established anti-inflammatory and antioxidant properties. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.